BC Platforms Partners with Dartmouth-Hitchcock Hospital to Transform Cancer Research

BASEL, SWITZERLAND - Feb 13, 2017 -

BC Platforms, a world leader in genomic data management solutions, today announces it has signed a partnership with Dartmouth-Hitchcock Medical Centers laboratory of Clinical Genomics and Advanced Technology in the Department of Pathology & Laboratory Medicine in the US, focused on providing data management solutions in cancer research.

BC Platforms will link clinical and genomic data from Dartmouth-Hitchcocks tumour biobank to enable rapid statistical analysis of the patient population via the BC|GENOME toolset. BC Platforms will also provide Dartmouth-Hitchcock with BC|PREDICT to facilitate the rapid elucidation of disease related genes from next generation sequencing data. The goal of the partnership is to provide valuable information for translational research to transform the way that cancer is being treated.

We are excited to be working with BC Platforms genomic data management modules, noted Dr. Wendy A. Wells, Chair of Pathology & Laboratory Medicine at Dartmouth-Hitchcock. These modules will further enhance our genomic research by providing a vital link to our institutional Bio-Repository.

Tero Silvola, Chief Executive Officer at BC Platforms, commented: We are delighted to be working in partnership with Dartmouth-Hitchcock to support translational research initiatives in cancer. Together we will explore the use of BC Platforms tertiary analysis tools for individual cancer patients but also explore the function of large batch automated analysis to establish common denominators in disease progression.

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms' vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.

We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. Our management team consists of industry leaders with over 100 years of combined experience in life sciences, computational biology and industrial technology. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.

AboutDartmouth-Hitchcock

DARTMOUTH-HITCHCOCK (D-H) is a nonprofit academic health system serving communities in northern New England. D-H provides access to more than 1,000 primary care doctors and specialists in almost every area of medicine at Dartmouth-Hitchcock Medical Center; the Norris Cotton Cancer Center, the Childrens Hospital at Dartmouth-Hitchcock, four affiliate hospitals, 24 ambulatory clinics and through the Visiting Nurse and Hospice for VT and NH. The D-H system trains nearly 400 residents and fellows annually, and performs world-class research, in partnership with the Audrey and Theodor Geisel School of Medicine at Dartmouth and the White River Junction VA Medical Center.